Zoetis Inc. (NYSE:ZTS) Shares Sold by SeaCrest Wealth Management LLC

SeaCrest Wealth Management LLC trimmed its position in Zoetis Inc. (NYSE:ZTS) by 9.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 3,785 shares of the company’s stock after selling 392 shares during the period. SeaCrest Wealth Management LLC’s holdings in Zoetis were worth $641,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ZTS. Norges Bank acquired a new position in shares of Zoetis in the 4th quarter worth approximately $980,646,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Zoetis by 31.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after acquiring an additional 3,244,074 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new position in shares of Zoetis in the 4th quarter worth approximately $242,757,000. CIBC Private Wealth Group LLC lifted its holdings in shares of Zoetis by 122.6% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,448,665 shares of the company’s stock worth $285,923,000 after acquiring an additional 797,884 shares during the last quarter. Finally, Corient Private Wealth LLC lifted its holdings in shares of Zoetis by 44.4% in the 4th quarter. Corient Private Wealth LLC now owns 1,953,508 shares of the company’s stock worth $385,564,000 after acquiring an additional 600,804 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the transaction, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at approximately $2,237,316. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.16% of the company’s stock.

Zoetis Trading Up 0.4 %

Shares of NYSE:ZTS opened at $175.57 on Thursday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company’s 50 day moving average is $169.73 and its two-hundred day moving average is $178.25. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. The company has a market cap of $80.11 billion, a PE ratio of 33.83, a P/E/G ratio of 2.72 and a beta of 0.86.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The company had revenue of $2.19 billion for the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.31 EPS. Equities analysts predict that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be given a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is 33.33%.

Analyst Ratings Changes

Several equities analysts have recently commented on ZTS shares. Stifel Nicolaus decreased their price objective on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. HSBC decreased their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. The Goldman Sachs Group cut their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research note on Monday, May 6th. Finally, Barclays cut their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $211.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.